| __timestamp | Johnson & Johnson | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21954000000 | 90480000 |
| Thursday, January 1, 2015 | 21203000000 | 133384000 |
| Friday, January 1, 2016 | 19945000000 | 179997000 |
| Sunday, January 1, 2017 | 21420000000 | 220119000 |
| Monday, January 1, 2018 | 22540000000 | 258528000 |
| Tuesday, January 1, 2019 | 22178000000 | 198205000 |
| Wednesday, January 1, 2020 | 22084000000 | 181022000 |
| Friday, January 1, 2021 | 20118000000 | 198359000 |
| Saturday, January 1, 2022 | 19046000000 | 208789000 |
| Sunday, January 1, 2023 | 20112000000 | 211124000 |
| Monday, January 1, 2024 | 21969000000 |
Cracking the code
In the world of corporate finance, Selling, General, and Administrative (SG&A) expenses are a critical measure of a company's operational efficiency. This chart compares the SG&A expenses of two prominent companies, Johnson & Johnson and MiMedx Group, Inc., from 2014 to 2023.
Johnson & Johnson, a global healthcare giant, consistently reported SG&A expenses in the range of $19 billion to $22 billion annually. Despite a slight decline of about 9% from 2014 to 2022, the company maintained a robust financial position. In contrast, MiMedx Group, Inc., a smaller player in the biopharmaceutical sector, saw its SG&A expenses grow by approximately 133% over the same period, reflecting its aggressive expansion strategy.
This comparison highlights the contrasting financial strategies of a well-established corporation versus a rapidly growing company, offering valuable insights into their operational priorities.
Who Optimizes SG&A Costs Better? Johnson & Johnson or Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: Johnson & Johnson vs Biogen Inc.
Breaking Down SG&A Expenses: Johnson & Johnson vs Insmed Incorporated
Comparing SG&A Expenses: Johnson & Johnson vs Apellis Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Johnson & Johnson vs Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and Wave Life Sciences Ltd.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and MiMedx Group, Inc.
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and MiMedx Group, Inc.
Catalyst Pharmaceuticals, Inc. or MiMedx Group, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Amphastar Pharmaceuticals, Inc. and MiMedx Group, Inc.
Who Optimizes SG&A Costs Better? Evotec SE or MiMedx Group, Inc.